GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annji Pharmaceutical Co Ltd (ROCO:7754) » Definitions » EV-to-FCF

Annji Pharmaceutical Co (ROCO:7754) EV-to-FCF : -10.13 (As of Dec. 14, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Annji Pharmaceutical Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Annji Pharmaceutical Co's Enterprise Value is NT$2,204.2 Mil. Annji Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-217.6 Mil. Therefore, Annji Pharmaceutical Co's EV-to-FCF for today is -10.13.

The historical rank and industry rank for Annji Pharmaceutical Co's EV-to-FCF or its related term are showing as below:

ROCO:7754' s EV-to-FCF Range Over the Past 10 Years
Min: -44.07   Med: -31.02   Max: -10.11
Current: -10.11

During the past 3 years, the highest EV-to-FCF of Annji Pharmaceutical Co was -10.11. The lowest was -44.07. And the median was -31.02.

ROCO:7754's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 8.19 vs ROCO:7754: -10.11

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-14), Annji Pharmaceutical Co's stock price is NT$31.50. Annji Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-3.950. Therefore, Annji Pharmaceutical Co's PE Ratio (TTM) for today is At Loss.


Annji Pharmaceutical Co EV-to-FCF Historical Data

The historical data trend for Annji Pharmaceutical Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annji Pharmaceutical Co EV-to-FCF Chart

Annji Pharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23
EV-to-FCF
- - -

Annji Pharmaceutical Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24
EV-to-FCF - - - - -

Competitive Comparison of Annji Pharmaceutical Co's EV-to-FCF

For the Biotechnology subindustry, Annji Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Annji Pharmaceutical Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annji Pharmaceutical Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Annji Pharmaceutical Co's EV-to-FCF falls into.



Annji Pharmaceutical Co EV-to-FCF Calculation

Annji Pharmaceutical Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2204.221/-217.611
=-10.13

Annji Pharmaceutical Co's current Enterprise Value is NT$2,204.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Annji Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-217.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Annji Pharmaceutical Co  (ROCO:7754) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Annji Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=31.50/-3.950
=At Loss

Annji Pharmaceutical Co's share price for today is NT$31.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Annji Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-3.950.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Annji Pharmaceutical Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Annji Pharmaceutical Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Annji Pharmaceutical Co Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Zhongxiao E. Raod, 16th Floor-6, No. 508, Sector 7, Nangang Distrist, Taipei, TWN, 115011
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.

Annji Pharmaceutical Co Headlines

No Headlines